5405962022-04-012022-09-305405962022-09-305405962022-04-012022-09-30RelatedPartyTransactionDomain15405962022-03-31RelatedPartyTransactionDomain15405962022-09-30RelatedPartyTransactionDomain15405962022-04-012022-09-30RelatedPartyTransactionDomain25405962022-03-31RelatedPartyTransactionDomain25405962022-09-30RelatedPartyTransactionDomain25405962022-04-012022-09-30RelatedPartyTransactionDomain35405962022-03-31RelatedPartyTransactionDomain35405962022-09-30RelatedPartyTransactionDomain35405962022-04-012022-09-30RelatedPartyTransactionDomain45405962022-03-31RelatedPartyTransactionDomain45405962022-09-30RelatedPartyTransactionDomain45405962022-04-012022-09-30RelatedPartyTransactionDomain55405962022-03-31RelatedPartyTransactionDomain55405962022-09-30RelatedPartyTransactionDomain55405962022-04-012022-09-30RelatedPartyTransactionDomain65405962022-03-31RelatedPartyTransactionDomain65405962022-09-30RelatedPartyTransactionDomain65405962022-04-012022-09-30RelatedPartyTransactionDomain75405962022-03-31RelatedPartyTransactionDomain75405962022-09-30RelatedPartyTransactionDomain75405962022-04-012022-09-30RelatedPartyTransactionDomain85405962022-03-31RelatedPartyTransactionDomain85405962022-09-30RelatedPartyTransactionDomain85405962022-04-012022-09-30RelatedPartyTransactionDomain95405962022-03-31RelatedPartyTransactionDomain95405962022-09-30RelatedPartyTransactionDomain95405962022-04-012022-09-30RelatedPartyTransactionDomain105405962022-03-31RelatedPartyTransactionDomain105405962022-09-30RelatedPartyTransactionDomain105405962022-04-012022-09-30RelatedPartyTransactionDomain115405962022-03-31RelatedPartyTransactionDomain115405962022-09-30RelatedPartyTransactionDomain115405962022-04-012022-09-30RelatedPartyTransactionDomain125405962022-03-31RelatedPartyTransactionDomain125405962022-09-30RelatedPartyTransactionDomain125405962022-04-012022-09-30RelatedPartyTransactionDomain135405962022-03-31RelatedPartyTransactionDomain135405962022-09-30RelatedPartyTransactionDomain135405962022-04-012022-09-30RelatedPartyTransactionDomain145405962022-03-31RelatedPartyTransactionDomain145405962022-09-30RelatedPartyTransactionDomain145405962022-04-012022-09-30RelatedPartyTransactionDomain155405962022-03-31RelatedPartyTransactionDomain155405962022-09-30RelatedPartyTransactionDomain155405962022-04-012022-09-30RelatedPartyTransactionDomain165405962022-03-31RelatedPartyTransactionDomain165405962022-09-30RelatedPartyTransactionDomain165405962022-04-012022-09-30RelatedPartyTransactionDomain175405962022-03-31RelatedPartyTransactionDomain175405962022-09-30RelatedPartyTransactionDomain175405962022-04-012022-09-30RelatedPartyTransactionDomain185405962022-03-31RelatedPartyTransactionDomain185405962022-09-30RelatedPartyTransactionDomain185405962022-04-012022-09-30RelatedPartyTransactionDomain195405962022-03-31RelatedPartyTransactionDomain195405962022-09-30RelatedPartyTransactionDomain195405962022-04-012022-09-30RelatedPartyTransactionDomain205405962022-03-31RelatedPartyTransactionDomain205405962022-09-30RelatedPartyTransactionDomain205405962022-04-012022-09-30RelatedPartyTransactionDomain215405962022-03-31RelatedPartyTransactionDomain215405962022-09-30RelatedPartyTransactionDomain215405962022-04-012022-09-30RelatedPartyTransactionDomain225405962022-03-31RelatedPartyTransactionDomain225405962022-09-30RelatedPartyTransactionDomain225405962022-04-012022-09-30RelatedPartyTransactionDomain235405962022-03-31RelatedPartyTransactionDomain235405962022-09-30RelatedPartyTransactionDomain235405962022-04-012022-09-30RelatedPartyTransactionDomain245405962022-03-31RelatedPartyTransactionDomain245405962022-09-30RelatedPartyTransactionDomain245405962022-04-012022-09-30RelatedPartyTransactionDomain255405962022-03-31RelatedPartyTransactionDomain255405962022-09-30RelatedPartyTransactionDomain255405962022-04-012022-09-30RelatedPartyTransactionDomain265405962022-03-31RelatedPartyTransactionDomain265405962022-09-30RelatedPartyTransactionDomain265405962022-04-012022-09-30RelatedPartyTransactionDomain275405962022-03-31RelatedPartyTransactionDomain275405962022-09-30RelatedPartyTransactionDomain275405962022-04-012022-09-30RelatedPartyTransactionDomain285405962022-03-31RelatedPartyTransactionDomain285405962022-09-30RelatedPartyTransactionDomain285405962022-04-012022-09-30RelatedPartyTransactionDomain295405962022-03-31RelatedPartyTransactionDomain295405962022-09-30RelatedPartyTransactionDomain295405962022-04-012022-09-30RelatedPartyTransactionDomain305405962022-03-31RelatedPartyTransactionDomain305405962022-09-30RelatedPartyTransactionDomain305405962022-04-012022-09-30RelatedPartyTransactionDomain315405962022-03-31RelatedPartyTransactionDomain315405962022-09-30RelatedPartyTransactionDomain315405962022-04-012022-09-30RelatedPartyTransactionDomain325405962022-03-31RelatedPartyTransactionDomain325405962022-09-30RelatedPartyTransactionDomain325405962022-04-012022-09-30RelatedPartyTransactionDomain335405962022-03-31RelatedPartyTransactionDomain335405962022-09-30RelatedPartyTransactionDomain335405962022-04-012022-09-30RelatedPartyTransactionDomain345405962022-03-31RelatedPartyTransactionDomain345405962022-09-30RelatedPartyTransactionDomain345405962022-04-012022-09-30RelatedPartyTransactionDomain355405962022-03-31RelatedPartyTransactionDomain355405962022-09-30RelatedPartyTransactionDomain355405962022-04-012022-09-30RelatedPartyTransactionDomain365405962022-03-31RelatedPartyTransactionDomain365405962022-09-30RelatedPartyTransactionDomain365405962022-04-012022-09-30RelatedPartyTransactionDomain375405962022-03-31RelatedPartyTransactionDomain375405962022-09-30RelatedPartyTransactionDomain375405962022-04-012022-09-30RelatedPartyTransactionDomain385405962022-03-31RelatedPartyTransactionDomain385405962022-09-30RelatedPartyTransactionDomain385405962022-04-012022-09-30RelatedPartyTransactionDomain395405962022-03-31RelatedPartyTransactionDomain395405962022-09-30RelatedPartyTransactionDomain395405962022-04-012022-09-30RelatedPartyTransactionDomain405405962022-03-31RelatedPartyTransactionDomain405405962022-09-30RelatedPartyTransactionDomain405405962022-04-012022-09-30RelatedPartyTransactionDomain415405962022-03-31RelatedPartyTransactionDomain415405962022-09-30RelatedPartyTransactionDomain415405962022-04-012022-09-30RelatedPartyTransactionDomain425405962022-03-31RelatedPartyTransactionDomain425405962022-09-30RelatedPartyTransactionDomain425405962022-04-012022-09-30RelatedPartyTransactionDomain435405962022-03-31RelatedPartyTransactionDomain435405962022-09-30RelatedPartyTransactionDomain435405962022-04-012022-09-30RelatedPartyTransactionDomain445405962022-03-31RelatedPartyTransactionDomain445405962022-09-30RelatedPartyTransactionDomain445405962022-04-012022-09-30RelatedPartyTransactionDomain455405962022-03-31RelatedPartyTransactionDomain455405962022-09-30RelatedPartyTransactionDomain455405962022-04-012022-09-30RelatedPartyTransactionDomain465405962022-03-31RelatedPartyTransactionDomain465405962022-09-30RelatedPartyTransactionDomain465405962022-04-012022-09-30RelatedPartyTransactionDomain475405962022-03-31RelatedPartyTransactionDomain475405962022-09-30RelatedPartyTransactionDomain475405962022-04-012022-09-30RelatedPartyTransactionDomain485405962022-03-31RelatedPartyTransactionDomain485405962022-09-30RelatedPartyTransactionDomain485405962022-04-012022-09-30RelatedPartyTransactionDomain495405962022-03-31RelatedPartyTransactionDomain495405962022-09-30RelatedPartyTransactionDomain495405962022-04-012022-09-30RelatedPartyTransactionDomain505405962022-03-31RelatedPartyTransactionDomain505405962022-09-30RelatedPartyTransactionDomain50iso4217:INRxbrli:pureERIS LIFESCIENCES LIMITED540596ERISNA2022-04-012023-03-31First half yearly2022-04-012022-09-30MillionstruetrueNANAfalsefalseEris Lifesciences LimitedAMIT BAKSHIManaging DirectorRemuneration50000000NA2439000025700002490000<DIV > <DIV> <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the director is paid against the services provided by them to the company. The said remuneration is specifically approved by the shareholders in their AGM meeting held on 01<SUP>st</SUP> September, 2021 (which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to this director and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedINDERJEET SINGH NEGIDirectorRemuneration13000000NA6200000730000670000<DIV > <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the director is paid against the services provided by them to the company. The said remuneration is specifically approved by the shareholders in their AGM meeting held on 01<SUP>st</SUP> September, 2021 (which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to this director and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Eris Lifesciences LimitedKAUSHAL SHAHDirectorRemuneration7500000NA3500000460000390000<DIV > <DIV> <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the director is paid against the services provided by them to the company. The said remuneration is specifically approved by the shareholders in their AGM meeting held on 01<SUP>st</SUP> September, 2020 (which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to this director and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedKRISHNAKUMAR VAIDYANATHANDirectorRemuneration45000000NA2243000020500002150000<DIV > <DIV> <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the director is paid against the services provided by them to the company. The said remuneration is specifically approved by the shareholders in their AGM meeting held on 01<SUP>st</SUP> September, 2021 (which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to this director and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedSachin ShahChief Financial OfficerRemuneration15000000NA7180000610000790000<DIV > <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the CFO is paid against the services provided by them to the company. The said remuneration is specifically approved by the Board of Directors vide circular resoution on 10-05-2022&nbsp;(which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to the CFO and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Eris Lifesciences LimitedMilind TalegaonkarCompany SecretaryRemuneration4300000NA1910000240000230000<DIV > <DIV> <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the CS is paid against the services provided by them to the company. The said remuneration is specifically approved by the Board of Directors vide circular resoution on 10-05-2022&nbsp;(which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to the CS and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedRAJEEV NAROTAM DALALIndependent directorRemuneration0NA195000000<DIV > <DIV>remuneration paid to independent director&nbsp;</DIV></DIV>Eris Lifesciences LimitedVIJAYA SAMPATHIndependent directorRemuneration0NA128000030000000Eris Lifesciences LimitedKALPANA VASANTRAI UNADKATIndependent directorRemuneration0NA220000035000000Eris Lifesciences LimitedPRASHANT GUPTAIndependent directorRemuneration0NA238000029800000Eris Lifesciences LimitedParv BakshiRelative of KMPRemuneration350000NA, under omnibus approval2700003000040000Eris Lifesciences LimitedAMIT BAKSHIManaging DirectorAny other transactionReimbursement0NA18000000Eris Lifesciences LimitedINDERJEET SINGH NEGIDirectorAny other transactionReimbursement0NA18000000Eris Lifesciences LimitedKAUSHAL SHAHDirectorAny other transactionReimbursement0NA18000000Eris Lifesciences LimitedKRISHNAKUMAR VAIDYANATHANDirectorAny other transactionReimbursement0NA19000000Eris Lifesciences LimitedSachin ShahChief Financial OfficerAny other transactionReimbursement0NA18000000Eris Lifesciences LimitedMilind TalegaonkarCompany SecretaryAny other transactionReimbursement0NA18000000Eris Lifesciences LimitedEris Healthcare Private LimitedWholly owned subsidiaryAny other transactionRoyalty Expense0Approved by Audit Committee on 29-07-2021 Audit committee has approved below mentioned criteria for Royalty amount For monthly net sales upto Rs. 9 Crores - Royalty to be 1% of monthly net sales For monthly net sales Rs. 9 Crores to Rs. 12 Crores - Royalty to be 3% of monthly net sales For monthly net sales above Rs. 12 Crores - Royalty to be 5% of monthly net sales113000000<DIV > <DIV>Since it is a transaction with wholly owned subsidiary it is exempt from Audit committee approval as per SEBI LODR Regulations. but the company has obtained the approval in audit committee&nbsp;</DIV></DIV>Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited) (Refer note 26) #Wholly owned subsidiaryAny other transactionRoyalty Expense0Approved by Audit Committee on 29-07-2021 Audit committee has approved below mentioned criteria for Royalty amount For monthly net sales upto Rs. 9 Crores - Royalty to be 1% of monthly net sales For monthly net sales Rs. 9 Crores to Rs. 12 Crores - Royalty to be 3% of monthly net sales For monthly net sales above Rs. 12 Crores - Royalty to be 5% of monthly net sales127000000<DIV > <DIV>Since it is a transaction with wholly owned subsidiary it is exempt from Audit committee approval as per SEBI LODR Regulations. but the company has obtained the approval in audit committee&nbsp;</DIV> <DIV></DIV></DIV>Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited) (Refer note 26) #Wholly owned subsidiaryAny other transactionRoyalty Income0Approved by Audit Committee on 29-07-2021 Audit committee has approved below mentioned criteria for Royalty amount For monthly net sales upto Rs. 9 Crores - Royalty to be 1% of monthly net sales For monthly net sales Rs. 9 Crores to Rs. 12 Crores - Royalty to be 3% of monthly net sales For monthly net sales above Rs. 12 Crores - Royalty to be 5% of monthly net sales279000000<DIV > <DIV>Since it is a transaction with wholly owned subsidiary it is exempt from Audit committee approval as per SEBI LODR Regulations. but the company has obtained the approval in audit committee&nbsp;</DIV> <DIV></DIV></DIV>Eris Lifesciences LimitedEris Healthcare Private LimitedWholly owned subsidiaryAny other transactionRoyalty Income0Approved by Audit Committee on 29-07-2021 Audit committee has approved below mentioned criteria for Royalty amount For monthly net sales upto Rs. 9 Crores - Royalty to be 1% of monthly net sales For monthly net sales Rs. 9 Crores to Rs. 12 Crores - Royalty to be 3% of monthly net sales For monthly net sales above Rs. 12 Crores - Royalty to be 5% of monthly net sales198000000<DIV > <DIV>Since it is a transaction with wholly owned subsidiary it is exempt from Audit committee approval as per SEBI LODR Regulations. but the company has obtained the approval in audit committee&nbsp;</DIV> <DIV></DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited) (Refer note 26) #Eris Healthcare Private LimitedGroup companyAny other transactionRoyalty Income0Approved by Audit Committee on 29-07-2021 Audit committee has approved below mentioned criteria for Royalty amount For monthly net sales upto Rs. 9 Crores - Royalty to be 1% of monthly net sales For monthly net sales Rs. 9 Crores to Rs. 12 Crores - Royalty to be 3% of monthly net sales For monthly net sales above Rs. 12 Crores - Royalty to be 5% of monthly net sales53000000<DIV > <DIV>The transaction is between two wholly owned subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee prior approval is not require as per SEBI LODR Regulations. but the company has obtained the approval in audit committee&nbsp;as mentioned in remarks.</DIV> <DIV></DIV></DIV>Eris Lifesciences LimitedEris Healthcare Private LimitedWholly owned subsidiaryInterest received0NA1367000000Eris Lifesciences LimitedEris Therapeutics LimitedWholly owned subsidiaryInterest received0NA380000000Eris Lifesciences LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)SubsidiaryInterest received0NA570000000<DIV > <DIV>At the time of execution of loan agreement the subsidiary was the wholly owned subsidiary and hence audit committee approval is not applicable</DIV></DIV>Eris Healthcare Private LimitedERIS PHARMACEUTICALS PRIVATE LIMITEDSubsidiaryInterest received0NA1000000<DIV > <DIV>The transaction is between two subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. </DIV></DIV>Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Wholly owned subsidiarySale of goods or services0NA3427000000<DIV > <DIV>Since it is a transaction with wholly owned subsidiary it is exempt from Audit committee approval as per SEBI LODR Regulations. </DIV></DIV>Eris Lifesciences LimitedEris Healthcare Private LimitedWholly owned subsidiarySale of goods or services0NA3078000000<DIV > <DIV> <DIV>Since it is a transaction with wholly owned subsidiary it is exempt from Audit committee approval as per SEBI LODR Regulations. </DIV></DIV></DIV>Eris Lifesciences LimitedEris Therapeutics LimitedWholly owned subsidiaryLoan0NA3940000000397110000Loan0.08On demandUnsecuredFor business<DIV > <DIV>Since it is a transaction with wholly owned subsidiary it is exempt from Audit committee approval as per SEBI LODR Regulations. </DIV></DIV>Eris Lifesciences LimitedEris Healthcare Private LimitedWholly owned subsidiaryLoan0NA70000000264850000347160000Loan0.08On demandUnsecuredFor business<DIV >Since it is a transaction with wholly owned subsidiary it is exempt from Audit committee approval as per SEBI LODR Regulations <DIV></DIV></DIV>Eris Lifesciences LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited) (Refer note 26) #SubsidiaryLoan0NA046410000326750000Loan0.08On demandUnsecuredFor business<DIV > <DIV>At the time of execution of loan agreement the subsidiary was the wholly owned subsidiary and hence audit committee approval is not applicable</DIV> <DIV></DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Healthcare Private LimitedGroup companyLoan0NA0132130000126370000Loan0.08On demandUnsecuredFor business<DIV > <DIV>The transaction is between two wholly&nbsp;subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. </DIV> <DIV></DIV></DIV>Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited) (Refer note 26) #Wholly owned subsidiaryAny other transactionTrade Recievable0NA08000001100000Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited) (Refer note 26) #Eris Healthcare Private LimitedGroup companyAny other transactionTrade Recievable0NA00360000<DIV > <DIV>The transaction is between two wholly subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. </DIV> <DIV></DIV></DIV>Eris Lifesciences LimitedEris Healthcare Private LimitedWholly owned subsidiaryAny other transactionAdvances to Creditors0NA03350000930000Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)Group companyAny other transactionOther Current asset0NA090800009080000<DIV > <DIV>The transaction is between two subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. </DIV> <DIV></DIV></DIV>Eris Lifesciences LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)SubsidiaryLoan0NA2754300003267500000Loan0.08On demandUnsecuredFor Business<DIV > <DIV>At the time of execution of loan agreement the subsidiary was the wholly owned subsidiary and hence audit committee approval is not applicable</DIV> <DIV></DIV></DIV>Eris Healthcare Private LimitedERIS PHARMACEUTICALS PRIVATE LIMITEDSubsidiaryLoan0NA0100000100000Loan0.08On demandUnsecuredFor Business<DIV > <DIV> <DIV>The transaction is between two subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. </DIV></DIV></DIV>Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Wholly owned subsidiaryAny other transactionPerpetual bond investment0NA0200000000200000000Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Healthcare Private LimitedGroup companyAny other transactionPerpetual bond investment0NA03000000030000000<DIV > <DIV> <DIV>The transaction is between two wholly subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. </DIV></DIV></DIV>Eris Lifesciences LimitedSUJESH VASUDEVANIndependent directorRemuneration0NA72000000Eris Lifesciences LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)SubsidiaryAny other transactionPreference share750000000Approved by Audit Committee on 03-12-20211500000001500000000Eris Lifesciences LimitedEris Healthcare Private LimitedWholly owned subsidiaryAny other transactionPurchase0NA33000000Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)Eris Lifesciences LimitedHolding companyAny other transactionTrade payable0NA0880000110000Eris Oaknet Healthcare Private LimitedEris Lifesciences LimitedHolding companyLoan0NA3250000000330900000Loan0.08On demandUnsecuredFor Business<DIV > <DIV>Eris Oaknet is a wholly owned subsidiary of Eris</DIV></DIV>Eris Lifesciences LimitedEris Therapeutics LimitedWholly owned subsidiaryAny other transactionPreference share0NA0249980000249980000Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Lifesciences LimitedHolding companyAny other transactionAdvances to Creditors0NA038100000<DIV > <DIV>Aprica Healthcare Limited is a wholly owned subsidiary of Eris</DIV> <DIV></DIV></DIV>Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)M. J. Biopharm Private LimitedShareholderAny other transactionPurchase0NA2057000000<DIV > <DIV>M. J. Biopharm is not a Related party hence the transaction mentioned is not a related party transaction</DIV></DIV>Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited) (Refer note 26) #M. J. Biopharm Private LimitedShareholderAny other transactionTrade payable0NA0252500001070000<DIV > <DIV>M. J. Biopharm is not a Related party hence the transaction mentioned is not a related party transaction</DIV> <DIV></DIV></DIV>Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited) (Refer note 26) #M. J. Biopharm Private LimitedShareholderAny other transactionLicensing fees0NA15000000000<DIV > <DIV></DIV> <DIV>M. J. Biopharm is not a Related party hence the transaction mentioned is not a related party transaction</DIV></DIV>